Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heart Failure Society Of America, FDA Seek Consensus On Trial Endpoints

This article was originally published in The Gray Sheet

Executive Summary

Representatives of the Heart Failure Society of America and FDA likely will meet this fall to develop an HFSA position paper on heart failure device clinical trial endpoints, HFSA says

You may also be interested in...

Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality

FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1

CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel

Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts